Background-Two endophenotypes of arterial calcification, calcification on arterial wall and calcification in atherosclerotic plaques, are associated with different types of cardiovascular events. Mgp-deficient mice showed matrix Gla protein (MGP) is strongly associated with calcification on arterial wall without atherosclerotic plaques, and MGP variants were not significantly associated with myocardial infarction. MGP may play different roles in the 2 endophenotypes. Methods and Results-We analyzed the associations of MGP variants rs4236, rs1800801, and rs1800802 with the 2 endophenotypes determined by multidetector computed tomography angiography. A total of 585 with calcification on coronary artery wall, 675 with calcification in coronary atherosclerotic plaques, 454 with calcification on aortic wall, and 725 controls were enrolled. After Bonferroni correction, rs4236 and rs1800801 were still associated with calcification on arterial wall, the odds ratios were 0.708 (95% confidence interval, 0.540-0.928) for rs4236 and 0.652 (95% confidence interval, 0.479-0.888) for rs1800801 in coronary artery wall calcification, and 0.699 (95% confidence interval, 0.525-0.931) for rs4236 and 0.650 (95% confidence interval, 0.467-0.905) for rs1800801 in aortic wall calcification, respectively. The variants were correlated with calcification severity by ln(CAC Agatston score+1) in coronary artery wall calcification but not in atherosclerotic plaque calcification. In accordance with their associations with calcification on arterial wall, rs4236C and rs1800801A were associated with higher MGP plasma levels, whereas rs1800802C was associated with lower MGP levels in normal controls. Because of the role of calcification in plaque vulnerability, their associations with acute myocardial infarction were also determined in 771 controls and 752 patients, no association was found. Conclusions-MGP genetic variants showed association with calcification on arterial wall but not with calcification in atherosclerotic plaques. (Circ Cardiovasc Genet. 2013;6:271-278.) The online-only Data Supplement is available at http://circgenetics.ahajournals.org/lookup/suppl/
G enetic and biochemical studies have established matrix
Gla protein (MGP) as the first protein known to act as a calcification inhibitor in vivo. Vascular calcification is a complex process resembling bone formation. [1] [2] [3] MGP plays a central role in the inhibition of calcification by influencing the function of bone morphogenetic protein type 2 and preventing the deposition of calcium in the vascular matrix. 4, 5 Animal and human data support the hypothesis that MGP is an important regulator of vascular calcification. But studies on the relationship of MGP levels with coronary artery calcification (CAC) gave conflicting results. [6] [7] [8] Meanwhile, MGP common genetic variants, such as rs1800801, 1800802, and rs4236, have been found to be functional, but their associations with CAC and coronary artery disease (CAD) are also conflicting. [9] [10] [11] Rescue experiments in Mgp null mice demonstrated that MGP acts locally in the vascular tissue as restoration of MGP expression in arteries completely rescued the arterial mineralization phenotype, whereas hepatic MGP expression, resulting in high systemic MGP levels, did not. 12 So detectable MGP circulating levels do not necessarily reflect MGP tissue levels of the vasculature, 13 which may be one explanation for the conflicting observations. The combination analysis of different endophenotypes of arterial calcification may be another explanation. There may be different mechanisms underlying calcification inhibition of MGP in the 2 endophenotypes, calcification on arterial wall and calcification in arterial atherosclerotic plaques. The Mgp-deficient mice displayed no phenotypic changes within the first 2 weeks. In 2-and 3-week-old Mgp knockout mice, there was calcification in the coronary arteries and aortic valves but not in the myocardium, and no fatty streak or atherosclerotic plaques were found in affected arteries. 14 The observation indicated that other gene products might function to prevent calcification earlier during development in the first 2 weeks, and MGP is strongly associated with calcification on arterial wall without atherosclerotic plaques. In our previous findings, 15 some patients with obvious calcification on coronary arterial wall (CAW), but no significant stenosis, had a reduced chance to have CAD. However, calcification occurring in atherosclerotic plaques was predominantly found in patients presenting with acute coronary syndrome [16] [17] [18] and could predict severely abnormal perfusion abnormalities 19 and coronary events. 20 Some have postulated that calcified plaques may represent older healed plaques, as compared with calcified components within a mixed calcified plaque, which have been proposed as intermediary in age between noncalcified and calcified plaques; however, this assertion, to date, has not been proven. 21 Multidetector computed tomography angiography (MDCTA) has been used noninvasively to examine arterial lesions directly and be a sensitive and specific tool for the detection of coronary stenosis and calcification. [22] [23] [24] [25] In this study, we analyzed the associations of MGP genetic variants with the 2 endophenotypes of arterial calcification, calcification on arterial wall and calcification in arterial atherosclerotic plaques, which were determined by MDCTA. We expected that these results could partially explain the conflicting associations of MGP genetic variants with CAC and could provide some clues to the underlying mechanisms.
Methods
All subjects self-reported as Han nationality, lived in north China, and provided written informed consent. The study was approved by the ethics committee of Fuwai Hospital, Chinese Academy of Medical Sciences.
Study Population With Arterial Calcification on the Wall or in the Plaque
Subjects in the first cohort were consecutively enrolled from patients 45 to 70 years of age who underwent MDCTA in Fuwai Hospital for diagnosing CAD from April 2007 to December 2010. The main complaints and signs of these patients were angina, atypical chest pain, and chest distress with multiple risk factors. Patients with calcification on aortic wall (AW), patients with calcification on CAW, patients with calcification in coronary atherosclerotic plaques (CAP), and control subjects were enrolled in this study. MDCTA was performed using a 64-slice multidetector scanner as previously described. 15, 26 The contrast-enhanced portion of the coronary lumen was compared with the mean value of proximal and distal nondiseased reference sites. Each lesion identified was examined using maximum intensity projection and multiplanar reconstruction techniques on short axis and along multiple longitudinal axes. In our population, there was no noncalcified component combined with calcification in the patients with calcification on CAW, and noncalcified tissue occupied >50% of the plaque area in each patients with calcification in CAP. The patients with aortic calcification were excluded in the 2 groups with calcification on CAW or calcification in CAP. In patients with calcification on AW, 28.6% were with calcification on CAW, and none of them was with calcification in CAP. CAC was quantified using the Agatston score method, incorporating both density and area. The sum of the scores in the left main, left anterior descending, circumflex, and right coronary arteries was considered the CAC score. Patients with aortic calcification were subgrouped by the severity of calcification as mild, moderate, and severe. This was evaluated in a visual qualitative manner. The results of imaging were independently reviewed by 2 radiologists blinded to randomized allocation. After making independent evaluations, a consensus interpretation was arrived at to obtain a final diagnosis. Subjects without arterial calcification or cardiovascular disease were enrolled as controls. All women enrolled in the study were postmenopausal. People with prior cardiovascular events that did not show narrowing of lumina, patients undergoing revascularization, and patients treated with coumarins were excluded. Patients with hematologic diseases, peptic ulcers, liver and kidney dysfunctions, infections, autoimmune diseases, and tumors were also excluded in this study.
Measurement of Plasma MGP Levels and Clinical Data Collection
Blood samples were collected after a 12-hour overnight fast before MDCTA. The plasma and cell buffet coat were kept at −70°C. Plasma total MGP was measured using an ELISA provided by CUSABIO BIOTECH company (Wuhan, Hubei, China). A complete clinical history was obtained from all subjects. In addition to neurological history and family history of hypertension, CAD, and diabetes mellitus, the following vascular risk factors were also recorded: history of vascular disease, cigarette smoking and alcohol consumption, body mass index, systolic blood pressure, diastolic blood pressure, blood glucose, highdensity lipoprotein-cholesterol, low-density lipoprotein-cholesterol lipids, total plasma cholesterol, and triglycerides. Plasma biochemical parameters were assayed by an automatic analyzer (Hitachi 7060, Hitachi, Japan). Low-density lipoprotein-cholesterol was calculated by the Friedewald formula. Hypertension was defined as a mean of 3 independent measures of blood pressure >140/90 mm Hg or the use of antihypertensive drugs. Diabetes mellitus was diagnosed when the subject had a fasting glucose >7.8 mmol/L or >11.1 mmol/L at 2 hours after oral glucose challenge, or used antidiabetic drugs. All lipids were determined in a CDC-qualified laboratory in Fuwai Hospital.
Study Population for Acute Myocardial Infarction
We identified patients with an initial clinical presentation of acute myocardial infarction by screening 20 000 patients admitted to Fuwai Hospital from December 2003 to June 2007. The diagnosis of acute myocardial infarction was defined according to guidelines 27 and received from clinical history. Patients with hematologic diseases, peptic ulcers, liver and kidney dysfunctions, infections, autoimmune diseases, and tumors were excluded. Age-(±5 years) and sex-matched controls were selected from subjects who underwent MDCTA as part of a routine checkup, whose major coronary artery had no more than 20% stenosis, and did not have any other vascular disease. Initially, 775 cases and 775 controls were recruited. Before data assessment, 27 subjects (23 cases, 4 controls) were excluded at different experimental stages because of insufficient DNA, lack of a definite diagnosis, and failure of genotyping.
Variants Selecting and Genotyping
The variants rs1800801 and rs1800802 are located in the promoter of MGP, whereas rs4236 results in a missense mutation from Thr to Ala. Herrmann et al 9 screened the polymorphisms of MGP and found that the rs1800801 or rs4236 could influence the calcification process affecting atherosclerotic plaques, and rs1800802 minor allele was associated with reduced promoter activity. Almost all of the following studies were focused on the 3 variants, including the promoter activity change, associations with serum/plasma MGP levels, CAC, kidney stone, etc. The 2 promoter variants might alter the binding of transcription factors to influence the expression of MGP. The rs4236 is located in exon 4 of the human MGP gene, and the corresponding amino acid is located at the COOH terminus (Arg-Lys-Arg-Arg-Gly-Thr-Lys) of MGP. The alteration of allele A(T) to G(C) leads to an amino acid change from Thr to Ala. The human MGP cDNA structure predicts an 84-residue, vitamin K-dependent MGP. 28 However, only 1 form of MGP, a 77-residue protein that lacked COOH-terminal residues, was detected in human bone extracts. This shortened MGP may result from COOH-terminal processing events. 29 The amino acid substitution in the COOH terminus may alter posttranslational modification of MGP and affect MGP halflife time. Hence, we analyzed the effect of the 2 promoter variants rs1800801 and rs1800802, as well as the exonic variant rs4236 on the endophenotypes and MGP levels.
A DNA isolation kit, RelaxGene Blood DNA System (Tiangen Inc, Beijing, China), was used for preparing genomic DNA by following the recommendations of the manufacturer. Genotyping was performed using MassARRAY high-throughput DNA analysis with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (Sequenom Inc, San Diego, CA). The primers were designed by MassARRAY Assay Design software (version 3.1). Variants were genotyped using iPLEX Gold technology (Sequenom) followed by an automated data analysis with the TYPER RT software version 4.0. Reproducibility of genotyping was confirmed by bidirectional sequencing in 500 samples, and the reproducibility was 99.4%.
Statistical Analysis
The distribution of quantitative variables was tested for normality using 1-sample Kolmogorov-Smirnov test. As triglycerides level was highly skewed, we compared the difference between cases and controls with Mann-Whitney nonparametric test. Quantitative variables were compared with the 1-way ANOVA test, including age, body mass index, blood pressure, glucose, total plasma cholesterol, triglycerides, highdensity lipoprotein-cholesterol, and low-density lipoprotein-cholesterol. A χ 2 test was used to test for qualitative variables, genotype/allele frequencies, and the Hardy-Weinberg equilibrium of the variants. The r 2 for linkage disequilibrium was calculated with online software 30 (http:// analysis2.bio-x.cn/SHEsisMain.htm). Relative risk (estimated as odds ratio) analysis was performed with 2×2 crosstabulation (crude odds ratio) and logistic regression (adjusted odds ratio) for the adjustment of conventional risk factors (age, sex, body mass index, systolic blood pressure, diastolic blood pressure, smoking, glucose, high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol, total plasma cholesterol, triglycerides, and hypertension and diabetes mellitus status). We used linear regression to assess the relation between ln(CAC score+1) and genotypes of each variant according to previous studies. 31, 32 In the genotype analysis, a dominant model was used because of similar changes of frequencies between heterozygote and homozygote of minor alleles. A 2-tailed P value of <0.05 was considered significant. Multiple testing was adjusted using Bonferroni correction, in which associations were evaluated at the α=0.017 (ie, 0.05/3) level of significance. Analyses were performed with SPSS 13.0 for Windows.
Results

Characteristics of the Population With Different Endophenotypes of Arterial Calcification
The clinical characteristics of the subjects in this population are shown in Table 1 . In the group with calcification on CAW, 53.2% were with a CAC score <20, 34.2% were in the range of 20 to 100, 10.1% were in the range of 100 to 400, and 2.6% were >400. In the group with calcification in CAP, 16.7% were with a CAC score <20, 30.4% were in the range of 20 to 100, 30.5% were in the range of 100 to 400, and 22.4% were >400. And in the group with calcification on AW, 18.1% were with mild calcification, 47.1% were with moderate calcification, and 34.8% were with severe calcification. The genotype distribution of the 3 variants is shown in Table I in the online-only Data Supplement. From the r 2 values (0.604 between rs4236 and rs1800801; 0.084 between rs4236 and rs1800802; and 0.050 between rs1800801 and rs1800802), there was weak linkage disequilibrium between rs4236 and rs1800801, whereas there was no linkage disequilibrium between rs1800802 and the other 2 variants. In a Japanese population, there is also no linkage disequilibrium among the 3 variants. 33 
MGP Variants rs4236 and rs1800801 Were Associated With Less Calcification on Arterial Wall but Not in Atherosclerotic Plaques
The distribution of these variants genotypes fulfilled expectations of the Hardy-Weinberg equilibrium in all groups. As shown in Table 2 , none of the 3 variants was significantly associated with calcification in CAP. In allelic analysis, the 3 variants were associated with calcification on arterial wall (both on AW and CAW) but not in CAP. In genotype analysis using a dominant model, the rs4236 and rs1800801 were associated with less calcification on arterial wall, but rs1800802 was not. After Bonferroni correction, the associations of the 2 variants rs4236 and rs1800801 with calcification on arterial wall remained significant.
Association of MGP Variants With Calcification on AW Was Stronger in Subgroup With Severe Calcification
The patients with calcification on AW were subgrouped by calcification severity as mild, moderate, and severe ( Table 3 ).
The association of the variants demonstrated an increased trend with calcification severity. The associations of rs4236 and rs1800801 were stronger in subgroup with severe calcification than those in other subgroups.
MGP Variants Were Correlated With Calcification Severity in Groups With Calcification on CAW but Not With Calcification in CAP
The genotypes of the 3 variants were correlated with ln(CAC score+1) in group with calcification on CAW but not in group with calcification in CAP ( Table 4 ). The rs1800802 showed an inverse relationship with ln(CAC score+1) compared with rs1800801 and rs4236. The rs4236 and rs1800801 were still negatively correlated with calcification severity after Bonferroni correction. MGP plasma levels were higher in CAP group but lower in CAW and AW groups, and no correlation was observed between MGP levels and calcification severity in any group.
We also detected the plasma MGP levels in this population, which were 66.7±27.1 ng/mL, 58.5±34.2 ng/mL, 62.3±34.1 ng/mL, and 78.6±37.6 ng/mL in control, AW, CAW, and CAP groups, respectively. The plasma MGP levels were higher in group with calcification in CAP, whereas the levels were lower in the 2 groups with calcification on arterial wall, including AW and CAW (all P<0.01). Lack of correlation between MGP levels and calcification severity could be observed in any group (Table II in 
MGP Levels Were Significantly Correlated With MGP Variant Genotypes in Control Group but Not in Other Groups
For rs4236 and rs1800801, MGP levels were significantly higher in the group with minor allele homozygotes and in the group with heterozygotes; for rs1800802, levels were significantly lower in the 2 groups (Figure) , when compared with those in subjects with major allele homozygotes. Linear regression model showed significant associations of the 3 variants with plasma MGP levels in the control group (allele coding was as the number of minor alleles). After adjustment with conventional risk factors, the β values were 10.9 (95% confidence interval, 1.5-20.3; P=0.023) for rs4236, 11.6 (95% confidence interval, 2.2-21.0; P=0.015) for rs1800801, and −14.0 (95% confidence interval, −26.6 to −1.4; P=0.028) for rs1800802. In the other 3 groups, no significant difference could be observed ( Table III in 
MGP Variants Were Not Associated With Acute Myocardial Infarction
In our first population, there was no noncalcified component combined with calcification in the patients with calcification on CAW, and noncalcified tissue was occupied >50% of the plaque area in each patient with calcification in CAP. We expected that the status of calcification in CAP in our population could resemble the mixed calcified plaque leading to the events. So we confirmed the association with calcification in Table 2 CAP in an acute myocardial infarction population. The characteristics of the enrolled subjects are shown in Table 5 . No association of the MGP variants with infarction was observed in this case-control study ( Table 6 ).
. Associations of MGP Variants With Calcification on Arterial Wall and Calcification in Coronary Atherosclerotic Plaques
Discussion
The present study is the first clinical investigation to dissect the associations of MGP genetic variants with 2 endophenotypes of arterial calcification (ie, calcification on arterial wall and calcification in atherosclerotic plaques). We also confirmed that the 3 variants may be functional according to their association with plasma MGP levels in normal controls. Because calcification occurring in atherosclerotic plaques were predominantly found in patients presenting with acute coronary syndrome, 17, 18 we also determined the associations of MGP variants with acute myocardial infarction. We demonstrated that (1) MGP genetic variants, rs4236 and rs1800801, were associated with less calcification on arterial wall but not with calcification in atherosclerotic plaques; (2) MGP levels were higher in groups with calcification in atherosclerotic plaque, whereas they were lower in groups with calcification on arterial wall, and the variants were correlated with plasma MGP levels only in control group; and (3) consistent with the results of calcification endophenotypes, the variants were not associated with acute myocardial infarction. Our data suggested different mechanisms under the calcification inhibition of MGP in calcification on arterial wall than in calcification in atherosclerotic plaques.
MGP contains 9 glutamate residues, 5 of which may be γ-carboxylated by the vitamin K-dependent γ-glutamate carboxylase. The ability of MGP to inhibit crystal growth depends on the presence of Gla residues, which could bind calcium in both solution and calcium salt crystals. 34, 35 But the degree of γ-carboxylation required for MGP to inhibit calcification in humans is not known. In addition to being carboxylated, MGP can also undergo a posttranslational phosphorylation, which is also thought to contribute to its functionality. 36 The phosphorylated undercarboxylated MGP accumulates in the vessel wall, whereas the dephosphorylated form is detectable in plasma. 37 The carboxylation is influenced by many enzymes involved in the process, vitamin K, etc. It is the same with phosphorylation, which is also influenced by many factors. Rescue experiments in MGP null mice demonstrated that MGP acts locally in the vascular tissue as restoration of MGP expression in arteries completely rescued the arterial mineralization phenotype, whereas hepatic MGP expression, resulting in high systemic MGP levels, did not. 12 So usually the circulating total MGP or undercarboxylated MGP levels, which we detected in plasma or serum, could not really reflect the locally active MGP levels around plaques.
Only significant correlation of the variants with plasma MGP was observed in the normal control group in our study. It is possible that confounding factors in the other groups may mask the real correlation, while the physiology conditions in normal controls are relatively simple. Serum MGP levels were found to be correlated with CAD risk factors and the Framingham CAD risk score. 6, 7 The associations were still insignificant after adjustment for conventional risk factors in our study. The calcification status may alter the mechanisms that are involved in the production/uptake of MGP plasma The correlation was shown with adjustment for age, sex, systolic blood pressure, diastolic blood pressure, body mass index, total plasma cholesterol, triglycerides, high-density lipoprotein-cholesterol, low-density lipoproteincholesterol, glucose, smoking, diabetes mellitus, and hypertension status. The allele coding was the number of minor alleles. CAC indicates coronary artery calcification; CAP, calcification in coronary atherosclerotic plaques; CAW, calcification on coronary artery wall; and CI, confidence interval. levels. In controls, they showed a normal physiological circumstance, in which the mechanism could be thought as of uniform. On the contrary, in the pathological circumstance, the mechanisms might demonstrate a significant difference. In an old population, 60 to 80 years of age, enrolled for assessing the effect of vitamin K supplementation on bone health and vascular calcification, 11, 38 they found that rs4236C and rs1800801A were significantly associated with more calcification on arterial wall, whereas rs1800802C was associated with less calcification on arterial wall. The trend was opposed with that in our control group. Further studies should be done to clarify the mechanism. Our results showed that plasma MGP levels were significantly higher in patients with calcification in CAP and lower in patients with calcification on AW or CAW compared with those in normal controls. Similarly, previous studies reported that MGP levels are higher in patients with atherosclerosis, 8 and undercarboxylated MGP serum levels are lower in patients with aortic valve calcification. 39 MGP levels are not associated with coronary calcification severity. 7, 40 We also found a lack of association of MGP levels with CAC score in CAP and CAW. Previous studies showed an inconsistent effect of the 3 variants on calcification in different phenotypes, including plaque calcification, CAC, myocardial infarction, kidney stone, and chronic kidney disease. In our study, the rs4236C and rs1800801A were significantly associated with less calcification on arterial wall, whereas rs1800802C was marginally associated with more calcification on arterial wall, which was consistent with some previous studies. 9, 33, [41] [42] [43] [44] There was also a lack of associations of rs1800802C in some studies, such as CAC, bone density, 10, 45 trachea calcification, costal cartilage calcification, Mönckeberg's medial calcific sclerosis, 41 and circulating MGP levels. 43 Maybe the marginal effect of rs1800802 was masked in these studies by other confounding factors. There should be more research on the variant, as well as the other 2 variants, to confirm the effects.
In our study, MGP variants rs4236 and rs1800801 were associated with calcification on arterial wall but not with calcification present in atherosclerotic plaques. In the process of vascular calcification, serum levels of undercarboxylated MGP initially rise because its production by vascular smooth muscle cells is triggered by calcium. In patients with calcification present in atherosclerotic plaques, the calcification is usually sequestered from arterial wall by other components of plaques, which influences the process of calcium inducing the production and deposition of undercarboxylated MGP. Active MGP is transformed from inactive form by some modifications, such as carboxylation and phosphorylation; the surrounding complex components may influence the activation of MGP. So the different surrounding environments may confer different mechanisms onto MGP inhibiting calcification in the 2 endophenotypes. Furthermore, we found that the variants were not associated with acute myocardial infarction, which means MGP may not play an important role in plaque vulnerability. Previous studies 3 demonstrated that risk of plaque rupture caused by calcification is biphasic and dose dependent on the basis of mechanical stress considerations. Failure stress tends to occur at interfaces between materials of different stiffness. Because calcified atherosclerotic plaque is much stiffer than cellular plaque, failure stress would be expected to concentrate at interfaces between calcified and noncalcified regions in the plaque. As the degree of calcification increases, the number of interfaces between rigid and distensible plaque initially would increase until the point at which the rigid plaques coalesce. Further calcification would result in a decreased interface area. Because failure stress concentrates at interface areas, it follows that risk of rupture increases with the degree of calcification to the point when plaques coalesce. Calcification beyond this point may be associated with decreasing risk of plaque rupture. In consideration of the role of calcification in plaque vulnerability, it was consistent with a lack of association between the variants and calcification in atherosclerotic plaques. Because this was an association study, the exact mechanisms of the associations of MGP variants with calcification only on arterial wall but not in plaque remain to be determined.
There were some strengths in our study. First, we used the novel endophenotypes of arterial calcification, calcification on the arterial wall and calcification in atherosclerotic plaques, to analyze the impact of MGP genetic variants on arterial calcification in a relatively large population for the first time; the mixing of the endophenotypes could result in the inconsistent findings on the associations between the MGP variants and arterial calcification. Second, consistent associations were observed among the 3 variants and calcification on arterial wall, whether the calcification was on CAW or aortic arterial wall. Third, rs4236 and rs1800801 were associated with higher MGP plasma levels, whereas rs1800802 was associated with lower MGP plasma levels in normal controls, which was consistent with the 3 variants with calcification on arterial wall. There were also some limitations. It would be very useful to assess MGP levels also in patients with acute myocardial infarction, but we could not get applicable serum or plasma for the determination. Second, because potential function of rs4236 is not significantly clarified from the cellular studies, the interpretation of the results has to be very careful. Third, MGP plasma levels do not necessarily reflect MGP tissue levels of the vasculature, and biochemical tests for the fully maturated circulating MGP (ie, both carboxylated and phosphorylated) are not available at the moment. Further studies should be done to improve our understanding of the regulation mechanisms of local and circulating MGP. Fourth, all the subjects were from 1 single clinical center. The association of MGP variants with calcification on arterial wall should be confirmed in other populations.
In summary, we demonstrate that MGP genetic variants are associated with calcification on arterial wall but not with calcification present in atherosclerotic plaques, suggesting different mechanisms of MGP in the 2 endophenotypes of arterial calcification, calcification on the arterial wall and calcification in atherosclerotic plaques.
